Navigation Links
Proteus

ProductsProteus
Company PlasmaSeal
Item Proteus
Features Totally automated push button operation. Minimal operator involvement. Single-use, fixed volume cartridge including hollow fiber concentrator. Dual action base unit with centrifuge and syringe pump. PPC preloaded in syringe at end of cycle. Fixed volume; 50 to 120 cc whole blood for 6 to 15 cc of PPC.
Description With Plasmaseal's Proteus device the two steps are performed in sequence automatically. Whole blood is injected into Proteus' single use disposable cartridge and placed in the dual action base unit. The operator touches a button, and the cycle begins. The platelet plasma is separated by centrifugation. Then the integral syringe pump concentrates fibrinogen, platelets and all other clotting and wound healing factors by circulating the platelet plasma through concentrator fibers. In ten minutes the PPC is ready for use. Proteus devices can be engineered to process 50 to 120 cc of whole blood, producing 6 to 15 cc of PPC.
Info PlasmaSeal
Customer Service: (415) 643-2760
Web site: http://www.plasmaseal.com/

Related medicine products :

1. BrachySource® I-125 Seed, Preloaded in Needle
2. TheraSeed® Pd-103 Seed, Preloaded in Needle
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products:
(Date:4/24/2017)... ... 2017 , ... Donna Parker, L. Ac. reads all sorts of books on ... to be very practical. She wanted to write a guide/workbook that would give readers ... It prompted her in writing “ A Clear Path to a Vibrant Life : ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue ... Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel ...
(Date:4/23/2017)... ... April 23, 2017 , ... "An event Horizon is ... the process rendered in my Art and Music. These are created as Metaphysical Transformations ... the boundary of mystery culminate to the ultimate singularity.", -- Karen Salicath Jamali , ...
(Date:4/22/2017)... (PRWEB) , ... April 22, 2017 , ... ... to his role as Vice President of Sales and Business Development at OAKWORKS, ... GPO/IDN business partner engagements, business development, and strategic planning for the company. ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary ... that youth violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright ... people involved in violence in the United States. The study, Trends in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
Breaking Medicine Technology: